BWBaojun Wang

Baojun Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Baojun Wang has a total of 358 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sex‐Specific Digital Phenotyping of Lower Urinary Tract Symptoms: A Cross‐Sectional Study of 1586 Adults From 35 Centers in China

    by Peixian Chen, Baojun Wang, Xiangjun Lyu, Caixia Zhang, Qingqing He, Qingwei Wang, Yanlan Yu, Lijuan Ren, Xiande Huang, Juan Chen, et al.

    Background and Purpose: Lower urinary tract symptoms (LUTS) represent a complex clinical syndrome with significant sexual dimorphism. Traditional “one‐size‐fits‐all” management often overlooks intra‐sex phenotypic heterogeneity. This study utilized unsupervised machine learning to identify sex‐specific digital phenotypes of LUTS within a large‐scale clinical cohort to provide a foundation for precision urological care. Materials and Methods: We analyzed a multicenter database of 1586 treatment‐seeking adults (1098 females, 488 males) across 35 centers. Baseline clinical characteristics and LUTS parameters from standardized voiding diaries and validated scales were collected. K‐means clustering was performed separately by sex to identify phenotypic subtypes, with the optimal number of clusters determined by the Elbow Method and visualized via Principal Component Analysis (PCA). Results: Significant sex‐specific disparities were observed: women reported a higher symptomatic burden across almost all domains but maintained better voiding satisfaction ( p < 0.001), while men exhibited poorer sleep quality ( p < 0.001). Clustering identified a consistent three‐subtype framework for both genders: Subtype 1 (Mild/Compensated): Characterized by the lowest symptom burden and highest tolerance. Subtype 2 (Storage‐Dominant with Sleep Fragmentation): Found in older populations, defined by severe nocturia, reduced bladder capacity, and profound sleep disruption. Subtype 3 (Voiding‐Dominant): Characterized by prominent dysuria and incomplete emptying. Conclusions: This exploratory sex‐stratified clustering study identified symptom‐based phenotypic patterns among treatment‐seeking Chinese adults with LUTS. These findings support the potential value of a subtype‐plus‐sex framework for LUTS assessment, but prospective validation using objective functional measures and treatment outcomes is needed.

  • Open Access

    Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China

    by Yujie Dong, Zhen Tian, Weilin Chen, Zhuoran Li, Zhiqiang Chen, Jieping Hu, Bin Fu, Xiaofeng Xu, Xu Zhang, Baojun Wang

  • Prognostic factors and the role of pelvic lymph node dissection in oligometastatic prostate cancer: a multicenter exploratory study

    by Jieping Hu, Yuyang Yuan, Xinchang Zou, Xiaoqiang Liu, Weipeng Liu, Yujie Dong, Baojun Wang, Bin Fu

    Background Oligometastatic prostate cancer (omPC) represents a specific state with improved outcomes following cytoreductive radical prostatectomy (cRP). Prognostic factors that guide disease progression are yet to be fully elucidated, and the role of pelvic lymph node dissection (LND) in this setting is controversial. This study aimed to evaluate the impact of LND on biochemical progression and castration-resistant prostate cancer (CRPC) in patients with omPC. Methods A total of 169 omPC patients who underwent cRP with (n = 123) or without LND (n = 46) between January 2015 and February 2024 at multiple centers were retrospectively analyzed. Biochemical progression-free survival (bPFS) and time to CRPC were analyzed using Kaplan–Meier curves and Cox proportional hazards models. Subgroup analysis stratified by nodal status was performed to explore differential treatment effects. Results In the overall cohort, multivariable analysis identified initial PSA > 30 ng/mL as an independent predictor of biochemical progression (HR = 2.53, 95% CI: 1.40–4.58, p = 0.002). For CRPC progression, no variable reached conventional statistical significance in the multivariable model. Stratified analysis revealed that among patients with node-positive disease (N1, n = 40), LND was associated with significantly prolonged bPFS (p = 0.018) and delayed progression to CRPC (p = 0.014). Notably, within the LND cohort (n = 123), N1 patients had significantly higher Gleason scores and T stages, and experienced worse CRPC than N0 patients (p = 0.02). Conclusion In omPC patients undergoing cRP, high baseline PSA independently predicted biochemical recurrence. Nodal involvement was associated with more aggressive disease features and worse outcomes within the population. An exploratory subgroup analysis suggested that node-positive patients may be associated with improved outcomes after LND; however, this finding was limited by a very small sample size and requires prospective validation.

  • Top Cited Papers

    Mapping the immune landscape of PCa: From tumor microenvironment to therapeutics

    by Shanhe Huang, Yuan Ou, Wei Zhuang, Jinxing Huang, Baojun Wang, Zean Li, Hai Huang


  • Open Access

    A Preclinical Study of a PSMA Ligand-Based Dual-Modality Probe for Radical Prostatectomy

    by Haoxi Zhou, Zhiqiang Chen, Long Yi, Baojun Wang, Shaoxi Niu, Yu Gao, Xu Zhang

    Purpose: Prostate-specific membrane antigen (PSMA) is a well-established molecular target in prostate cancer (PCa). Both radionuclide imaging and near-infrared fluorescence (NIRF) imaging offer high sensitivity for in vivo tumor detection. PSMA-targeted dual-modality probes integrating these two imaging techniques provide complementary preoperative and intraoperative tumor visualization, thereby improving surgical guidance in PCa. In this study, we aimed to develop a novel dual-labeled PSMA probe combining radioactive and fluorescent properties to achieve precise tumor delineation during radical prostatectomy (RP). Methods: A high-affinity PSMA-targeted fluorescent probe (PSMA-DF) was synthesized using solid-phase synthesis. Subsequent radiolabeling with the radionuclide [68Ga]Ga yielded the successful generation of a dual-modal PSMA-targeted molecular probe, namely [68Ga]Ga-PSMA-DF. The probe was systematically evaluated both in vitro and in vivo, and its safety profile was assessed through acute toxicity testing. Tumor-bearing nude mouse models were established using PSMA-positive 22Rv1 and PSMA-negative PC-3 PCa cell lines. Imaging performance, tumor-targeting specificity, and biodistribution of the probe were comprehensively evaluated using micro-PET imaging, in vivo fluorescence imaging, and biodistribution studies. Results: High-quality and high-purity PSMA-DF was successfully prepared, which exhibited excellent optical properties. Following radiolabeling with [68Ga]Ga, a dual-modality radionuclide-fluorescence probe ([68Ga]Ga-PSMA-DF) was successfully constructed. In vitro cellular uptake studies demonstrated that 22Rv1 cells had relatively high uptake of the probe, reaching 7.34 ± 0.55 IA%/106 cells at 120 min. In contrast, PC-3 cells and blocked 22Rv1 cells displayed minimal uptake, confirming the specific targeting ability of the probe. In vivo evaluations were conducted on tumor-bearing mice using micro-PET/CT and NIRF imaging. The results revealed that [68Ga]Ga-PSMA-DF achieved high specific tumor accumulation in 22Rv1 xenografts, with the peak tumor uptake (SUVmax = 1.748 ± 0.132) and tumor-to-muscle ratio (11.542 ± 1.511) observed at 120 min. Notably, high-contrast fluorescence imaging was also achieved at later time points, yielding a tumor-to-background ratio (TBR) of 6.559 ± 1.415 at 48 h. Notably, ex vivo biodistribution data were consistent with in vivo imaging findings. Conclusions: This preclinical study demonstrates that [68Ga]Ga-PSMA-DF exhibits high and specific uptake in PCa models, supporting its potential as a dual-modality tracer for both PET/CT imaging and real-time intraoperative fluorescence guidance during PCa surgery.


  • Open Access

    PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma

    by Liangyou Gu, Qi Zhang, Qiyang Liang, Cheng Peng, Yaohui Wang, Chenfeng Wang, Zhuoran Li, Yezhen Tan, Yanming Zhou, Qing Bi, et al.

    The combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has improved clinical outcomes in advanced renal cell carcinoma (aRCC), though therapeutic resistance remains a major challenge. We conducted single-cell transcriptomic analysis on 61 tumor samples from 34 aRCC patients treated with TKIs alone or in combination with ICIs. Non-responders exhibited increased neutrophil infiltration and enrichment of SAA+ tumor cells following treatment. We identified a VEGFA+CEACAM1+ neutrophil subset exhibiting immunosuppressive properties that is associated with poor clinical response. In vivo, pharmacologic inhibition of SAA enhanced sensitivity to ICI plus TKI combination therapy, while blockade of the CEACAM1–TIM-3 axis in humanized PD-1 mouse models significantly potentiated anti–PD-1 efficacy. Our study establishes a single-cell atlas of the aRCC tumor microenvironment under treatment pressure and identifies a previously unrecognized SAA–CEACAM1–TIM-3 axis driving drug resistance, highlighting potential targets to improve therapy efficacy.


  • Open Access

    Efficacy of neoadjuvant hormonal therapy combined with robot-assisted radical prostatectomy for oligometastatic prostate cancer: a multicenter retrospective study

    by Yujie Dong, Zhuoran Li, Zhiqiang Chen, Zhen Tian, Weilin Chen, Jieping Hu, Yuqi Jia, Jin Luo, Nanxin Zou, Jinqiao Li, et al.

    Objective: To evaluate the efficacy of neoadjuvant hormonal therapy (NHT) on perioperative and oncological outcomes in patients with oligometastatic prostate cancer (OmPCa) treated with robot-assisted radical prostatectomy (RARP) and adjuvant androgen-deprivation therapy (ADT). Methods: In this multicenter retrospective study, 160 OmPCa patients treated from five Chinese medical centers between May 2010 and May 2023 were included: 80 received NHT followed by RARP+ADT, and 80 underwent RARP+ADT alone. We evaluated surgical information, pathological findings, biochemical progression-free survival (bPFS), radiological progression-free survival (rPFS), overall survival (OS), subsequent treatments, and ADT-related adverse events. Results: Compared to the standard therapy (ST) group, the NHT group exhibited shorter operative time (170 vs. 200min; P = 0.030), less blood loss (100 vs. 200 mL; P = 0.022), lower positive surgical margin rate (17.50% vs. 37.50%; P = 0.005), and higher rates of pathological downstaging in T-stage (48.8% vs. 6.3%; P<0.001). More NHT patients achieved undetectable PSA (83.8% vs. 65.0%; P = 0.007) with a shorter time to PSA nadir (2 vs. 3 months; P = 0.002). After a median postoperative follow-up of 52 months, no significant differences were observed in bPFS, rPFS or OS between groups. However, subgroup analysis revealed significant interaction effects between NHT and biopsy Gleason score ≥8, seminal vesicle invasion, and clinical T stage ≥ T3 (all P-interaction0.05). Conclusion: NHT improves perioperative outcomes and reduces the need for subsequent salvage therapies in OmPCa patients undergoing RARP. It may offer oncological benefits, particularly those with a biopsy Gleason score ≥8 or clinical T-stage≥T3. It represents a safe and feasible neoadjuvant approach.


  • DR5/WDR12 balances p65 stability promoting sunitinib resistance in renal cell carcinoma

    by Wen Tao, Yuhao Dong, Shidong Zuo, Hanfeng Wang, Qiyang Liang, Tianwei Cai, Xinran Chen, Wenjie Wei, Chi Zhang, Shuo Tian, et al.

    Although the use of tyrosine kinase inhibitors (TKIs), such as sunitinib, has led to impressive advancements in the treatment of clear cell renal cell carcinoma (ccRCC), primary or acquired resistance to sunitinib remains elusive. Here, we report that death receptor 5 (DR5) is upregulated in ccRCC tissues and sunitinib-resistant cells, and is associated with poor outcomes and sunitinib resistance. Gain- and loss-of-function experiments revealed that DR5 promotes sunitinib resistance both in vitro and in vivo. Mechanistically, DR5 enhances the activation of NF-κB signalling by reducing the ubiquitin-mediated proteasomal degradation of p65 via competitive binding to the CUL4B-DDB1 E3 ligase complex linker protein WDR12, leading to the transcriptional upregulation of DR5 and BCL2. The positive feedback loop between DR5 and p65 contributes to the upregulation of BCL2 expression, which in turn modulates sunitinib resistance in ccRCC. Notably, targeting the DR5/NF-κB/BCL2 axis sensitizes ccRCC cells to sunitinib both in vitro and in vivo. Clinically, ccRCC patients with high DR5 expression show decreased responsiveness to TKI-based therapy. Collectively, these results highlight the importance of the positive feedback loop involving the DR5/NF-κB axis in sunitinib resistance and provide an effective therapeutic strategy for overcoming resistance.